Answers are grounded in this paper and cite their sources.
Artificial intelligence (AI) is becoming an important analytical capability in pharmaceutical sciences because modern drug research generates large, diverse and rapidly expanding datasets. Machine learning (ML), deep learning, natural language processing, knowledge graphs and generative models can support the identification of disease mechanisms, prioritization of therapeutic targets, screening of chemical libraries, prediction of molecular properties and interpretation of patient-level information. These methods do not replace laboratory experimentation, clinical judgement or regulatory assessment; rather, they can help researchers decide which hypotheses and candidates deserve further investigation. This review examines recent advances across drug discovery, computer-aided drug design and personalized medicine, with attention to the evidence required for translation into practice. AI-assisted target discovery combines genomics, transcriptomics, proteomics, metabolomics, imaging and biomedical literature. Predictive models can identify patterns associated with disease and rank candidate targets for experimental testing. In molecular design, structure-based prediction, ligand-based modelling and generative algorithms can propose or prioritize compounds with selected properties. Protein-structure prediction systems, including alphaFold, have expanded access to structural hypotheses, while newer interaction-prediction systems extend modelling to molecular complexes (Jumper et al., 2021; Abramson et al., 2024). Nevertheless, a predicted structure or high model score is not equivalent to demonstrated binding, biological activity, clinical benefit or safety. Personalized medicine applies computational methods to understand differences between patients. AI may integrate genomic variants, clinical characteristics, laboratory results, medication histories and real-world outcomes to support patient stratification, biomarker discovery and individualized treatment decisions. Pharmacogenomic information can be clinically useful for selected gene–drug pairs, but recommendations must be based on validated evidence and implemented with professional oversight (Relling and Evans, 2015; Caudle et al., 2020). Major barriers include incomplete and unrepresentative datasets, poor interoperability, privacy risks, model opacity, bias, reproducibility problems and uncertainty about regulatory responsibilities. The central conclusion is that AI is most valuable when it is embedded in a transparent, experimentally validated and clinically governed workflow. Future progress requires prospective evaluation, external validation, high-quality data, explainable outputs, cybersecurity, multidisciplinary collaboration and meaningful patient involvement. The review therefore considers both the technical promise and the practical conditions needed for responsible adoption across the pharmaceutical life cycle.
No takes yet. Share an insight, caveat, or question.
Soneja et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: